Acutegainfor BVS vs. DES: 1.15vs. 1.46 mm,p < 0.0001;IVUS showed lower post-procedure mean lumen area in BVS arm (4.9 vs. 5.7 mm2,p < 0.001)1-year scaffold thrombosis intwoBVSpatients;no stent thrombosis in DES armMACE: 4.8% vs. 3.0%,p = 0.35; target-vessel MI: 4.2% vs. 1.2%,p = 0.07; TLR: 1.2% vs. 1.8%,p = 0.69
Trial design:Patientsundergoing PCI were randomized in a 2:1 fashion toeither AbsorbbioabsorbableBVSorXiencedrug-eluting stent (DES). Patientswere followed for1 year.
SerruysP, et al. Lancet2014;Sep 14:[Epub]
MACE at 1 year
PCI with thebioabsorbableeverolimus-eluting stent, Absorb BVS, results ininferior post-procedural angiographic and IVUS outcomes,compared with thecobalt chromium-based (metallic)everolimus-eluting stent,XienceFirst head-to-head comparison of Absorb BVS toDES;adds to body of literature on BVS